Benitec Biopharma Inc. · NASDAQ:BNTC
Benitec Biopharma — Benitec — Investor Presentation (January 2004)
15 slides from Benitec Biopharma's investor presentation, January 2004
Slide 1: Benitec Limited
Benitec Limited January 2004
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Benitec Limited (“Benitec”) for general information purposes and while every care has been taken in relation to its accuracy or completeness, no warranty is given or implied. It is provided to you on the following basis: • This presentation is not an
Slide 3: Introduction
Introduction ¾ Publicly listed biotech company (ASX: BLT) founded in 1997 • Current market cap of $79m – 73.6m shares on issue • Headquartered in Brisbane, Queensland ¾ Specialize in R&D based on gene silencing with an aim to: • Discover and validate new drug targets • Develop new drugs and therapeu
Slide 4: Management Team
Management Team John McKinley 15 years Biotech experience in European public and Executive Chairman & CEO private biotech companies, as Director and CEO; formerly UK solicitor specializing in Company and IP law Prof. Ken Reed 30 years Biotech experience; formerly Director of Director, Research & Tec
Slide 5: Business Description - Highlights
Business Description - Highlights ¾ Innovative and proven platform technology in human/animal cells COMPETITIVE ADVANTAGES ¾ Platform technology recognized as 3rd biotech revolution ¾ Dominant intellectual property – over 50 patents: 7 granted, pending in 17 jurisdictions ¾ Internationally recognize
Slide 6: Technology – RNAi
Technology – RNAi ¾ A powerful new method for discovering and developing drugs based on targeted gene silencing ¾ Disease results from aberrant proteins, encoded by abnormal gene variants ¾ RNAi is a natural cellular mechanism that selectively negates gene expression • Improper protein synthesis is
Slide 7: Technology – DNA-directed RNAi
Technology – DNA-directed RNAi ¾ Specific destruction of messenger RNA (mRNA) by RNA interference (RNAi), triggered by DNA constructs ¾ Benitec pioneered DNA-directed RNAi (ddRNAi) and patented the technology in 1998 • DNA construct inserted into cell, which produces double stranded RNA (dsRNA) • si
Slide 8: Technology – RNAi Advantage
Technology – RNAi Advantage siRNAi ddRNAi Advantages to ddRNAi RNA-based DNA - based • INCREASED STABILITY – Ease of handling •COST SAVINGS – High throughout screening possible – expensive modifications unnecessary • Short dsRNA only • Variable length dsRNA • INCREASED APPLICABILITY – several genes
Slide 9: Technology – Reduced Pipeline
Technology – Reduced Pipeline The current path to traditional drug development... approx. 8–10 years Target Target Candidate Gene Target Lead Lead Preclinical Clinical Validation Validation Drug Discovery Identification Identification Optimization Testing Trials in vitro in vivo Screening Benitec’s
Slide 10: Commercial Strategy
Commercial Strategy ¾ Earlier revenue streams from discovery tools balanced against the higher risk and reward of commercial therapeutics BUSINESS MODEL ¾ Will support clinical program through to advanced trial status ¾ Reduced fundraising amounts during the development of commercial therapeutics ¾
Slide 11: Revenue Streams
Revenue Streams ¾ Business model involves two revenue streams: • Discovery R&D - short to medium term revenue 1. R&D Licensing 2. Retail Sales of 3. High Throughput 4. Transgenic and (Freedom to Operate) RNAi Materials in vitro Systemic in vivo Kits for Biotech companies Pharma “in-house” 1.1 Not fo
Slide 12: Promega Deal
Promega Deal ¾ Signed on April 8th, 2003 ¾ First licensing deal for Benitec ¾ Promega acquired worldwide exclusive license to develop, sell and distribute DNA- delivered RNAi (ddRNAi) products based upon Benitec's proprietary technology and to issue research licenses for non-therapeutic use ¾ ddRNAi
Slide 13: Milestones 2003
Milestones 2003 ¾ Opened US office ¾ Product roll-out – December ’03 ¾ Licenses and partnerships ¾ Patent grant – US and UK ¾ Investment: Total equity raising of AUD$10.92 million • 9.1 million new ordinary shares at $1.20 per share • Closing trading price AUD$1.27 (5th December 2003) • 3 month volu
Slide 14: Anticipated Milestones 2004
Anticipated Milestones 2004 ¾ Working capital funding ¾ US incorporation/office ¾ Recruitment of key business executives ¾ M&A access to US market/NASDAQ ¾ Patent grant in Europe, ROW & expanded portfolio ¾ Establish clinical development program ¾ Pre-clinical trial collaboration in the HIV field ¾
Slide 15: Investment Thesis
Investment Thesis ¾ Leading Gene Silencing Company • Unchallenged IP in ddRNAi, with exclusive rights for applications in humans • Superior to competing technologies ¾ Novel Technology Platform • Efficient and cost effective discovery applications • Shortened development timeline • Multiple therapeu